A Phase I Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma, or Other Tumors Potentially Dependent on Hedgehog Signaling Pathway

Status
Active
Cancer Type
Brain Cancer
Trial Phase
Phase I
Eligibility
12 to 17, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01125800
Protocol IDs
CLDE225X2104 (primary)
EUDRACT 2010-019348-37
Study Sponsor
Novartis Pharmaceuticals Corporation

Summary

This dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway

Treatment Sites in Georgia


Aflac Cancer and Blood Disorders Center of Children’s at Egleston
1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

Study Coordinator:
Sindy Midoro

Doctors:

Dolly Aguilera MD
Tobey J. MacDonald MD
Muna Qayed MD

Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
5455 Meridian Mark Road
Suite 400
Atlanta, GA 30342
404-785-2215
www.choa.org

Study Coordinator:
Sindy Midoro

Doctors:

Dolly Aguilera MD
Tobey J. MacDonald MD